CP 673451 is a pharmacologically selective PDGFR-beta inhibitor and PDGF-BB-stimulated autophosphorylation of PDGFR-beta in cells (IC50 = 1 nmol/L) being more than 450-fold selective for PDGFR-beta versus other angiogenic receptors. Inhibition of PDGFR-beta phosphorylation in tumors correlates with plasma and tumor levels of CP673451. A dose of 33 mg/kg was adequate to provide >50% inhibition of receptor for 4 hours corresponding to an EC50 of 120 ng/mL in plasma at C(max). In a sponge angiogenesis model, CP 673451 inhibited 70% of PDGF-BB-stimulated angiogenesis at a dose of 3 mg/kg (q.d. x 5, p.o., corresponding to 5.5 ng/mL at C(max)). In vivo, CP 673451 inhibits tumor PDGFR-beta phosphorylation, and it also selectively inhibits PDGF-BB-stimulated angiogenesis. CP 673451 causes significant tumor growth inhibition in multiple human xenograft models.
|Cell lines||H526 small cell lung cancer cells|
|Preparation method||For both assays, cells were starved overnight and treated the following day with increasing concentrations of CP-673,451 for 30 minutes at 37°C. During the final 5 to 8 minutes of incubation, either stem cell factor (50 ng/mL) or PDGF-BB (500 ng/mL) was added. Unstimulated cells were used as phosphorylation controls. Cells were washed, lysed, and equivalent protein levels were separated by PAGE. Following transfer to nitrocellulose, membranes were blotted to detect phospho-PDGFR (pY857 antibody, Santa Cruz) or phospho-c-kit (pY719 antibody, Cell Signaling) antibody at 1: 200 overnight at 4°C. Densitometry of bands and IC50 calculation were measured using a LumiImager (Roche, Indianapolis, IN).|
|Concentrations||0~3000 n M|
|Incubation time||30 min|
|Animal models||Mice bearing Colo205 tumors xenograft model|
|Dosages||10, 33, and 100 mg/kg twice daily for 10 days|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 40 mg/mL|
Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
Roberts WG, et al. Cancer Res. 2005 Feb 1;65(3):957-66. PMID: 15705896.
|Related VEGFR/PDGFR Products|
|EG00229 Trifluoroacetate salt
EG00229 Trifluoroacetate is the first small molecule inhibitor of the neuropilin-1 and VEGF-A interaction with an IC50 of inhibition of 8 uM (125I-VEGF binding to PAE/NRP1 cells).
Apatinib is a selective VEGFR2 inhibitor with IC50 of 1 nM.
JI-101 is an orally available multi-kinase inhibitor of VEGFR2，PDGFRβ and EphB4 with potential antiangiogenic and antineoplastic activities.
BAW2881 (NVP-BAW2881) is a potent and selective VEGFR2 inhibitor with activity to inhibit chronic and acute skin inflammation.
SU 1498 is a selective inhibitor of the receptor tyrosine kinase VEGF receptor 2 (VEGFR2, aka FLK1; IC50 = 700 nM).
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.